Heidelberg Pharma AG, a clinical-stage biopharmaceutical enterprise specializing in antibody-drug conjugates, generates trailing twelve-month revenues fluctuating around €8 million to €10 million (or roughly ₹830 million INR equivalent). Its financial inflows derive primarily from research collaborations, licensing agreements, and milestone payments rather than commercial product sales.